# OnCo record a071401 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/a071401/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "a071401", "NCT02523014" ;
  schema:name "Alliance A071401"@en ;
  schema:alternateName "A071401"@en, "NCI-2015-00546"@en ;
  schema:description "Alliance A071401 showed that a twice-daily tablet blocking the enzyme FAK kept more meningiomas with a faulty NF2 gene from growing at six months than history would predict, in both lower-grade and higher-grade tumours, the first mutation-matched treatment to show activity in this tumour."@en ;
  schema:url <https://onco.cc/trials/a071401/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02523014>, <https://doi.org/10.1200/JCO.21.02371> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/meningioma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/fak/> ;
  onco:drugs <https://onco.cc/drugs/gsk2256098/> ;
  onco:companies <https://onco.cc/companies/gsk/> ;
  onco:institutions <https://onco.cc/institutions/alliance-oncology/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-a071401-brastianos-jco-2023/> .